Revance Therapeutics
- Pharmaceutical Preparations
- Nashville, Tennessee
Compensation history
Top executives at Revance Therapeutics received an average of $3M per person in annual compensation from 2013 to 2021.
Average pay of disclosed executives at Revance Therapeutics
By year
- 2019
MF$17MMark J. FoleyPresident and Chief Executive OfficerLB$5ML. Daniel BrowneFormer President and Chief Executive OfficerAJ$2MAbhay JoshiChief Operating OfficerCM$1MCaryn G. McDowellSenior Vice President, General Counsel and Corporate SecretaryTS$1MTobin C. SchilkeChief Financial OfficerDS$801KDustin SjutsChief Commercial Officer
Executives
We found 13 executives who work or worked at Revance Therapeutics.
Mark Foley
Revance Therapeutics
Chief Executive Officer
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
Dustin Sjuts
Revance Therapeutics
President
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
Aubrey Rankin
Revance Therapeutics
Former President, Innovation & Technology
Dwight Moxie
Revance Therapeutics
General Counsel
L Browne
Revance Therapeutics
Chief Executive Officer
Caryn McDowell
Revance Therapeutics
General Counsel
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019
About Revance Therapeutics
- Industry classifications
- DivisionManufacturing
- Major groupChemicals And Allied Products
- Industry groupDrugs
- IndustryPharmaceutical Preparations
- Address1222 Demonbreun Street, Suite 2000, Nashville, Tennessee 37203
- Phone6157247755
- Fiscal year endDecember 31
Source: SEC filings on March 24, 2022, March 24, 2021, March 26, 2020, March 25, 2019, March 20, 2018, March 24, 2017, March 18, 2016, and March 26, 2015.